Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon output. GLP-1 peptides exhibit promising therapeutic outcomes in treating type 2